All Posts Tagged With: "SNY"

(PPHM) Peregrine Pharmaceuticals Shows Encouraging News

Peregrine Pharmaceuticals (PPHM) recently received encouraging news when the company announced that the US Food and Drug Administration (FDA) has agreed on the design for the phase III registration trial for its oncology candidate,...

26Sep2013 | | Comments Off | Continued

(SNY) Sanofi and Regeneron Pharmaceuticals Dupilumab Data Published

Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) recently announced that positive data from a phase IIa study evaluating dupilumab (REGN668/SAR231893)...

4Aug2013 | | Comments Off | Continued

(BMY) Bristol-Myers Squibb Company Earns Good News From FDA

Bristol-Myers Squibb Company (BMY) recently received positive news from the US Food and Drug Administration (FDA) when the US regulatory authority approved the pharma major’s HIV drug Sustiva for treating children between three months...

18May2013 | | Comments Off | Continued

(SNY) Sanofi Earnings Plummet – Outlook Maintained

Sanofi (SNY) reported first quarter 2013 business earnings of 81 cents per American Depository Share (ADS), below the Zacks Consensus Estimate of 89 cents. Earnings were down 29.0% at constant exchange rates (CER) from the year-ago...

16May2013 | | Comments Off | Continued

(LDL) Pivotal Therapeutics Progresses with Vascazen

Pivotal Therapeutics Inc. (PVTTF) recently announced encouraging top line data from the REVEAL study (n=110) on its cardiovascular candidate Vascazen in the US. Vascazen was successful in achieving the primary objective of the study...

27Apr2013 | | Comments Off | Continued

(REGN) Regeneron Pharmaceuticals Rated Neutral Again

We recently maintained our Neutral recommendation on biopharmaceutical company, Regeneron Pharmaceuticals (REGN). Our target price is $195.00 per share. Why the Reiteration? Regeneron reported higher-than-expected...

18Apr2013 | | Comments Off | Continued

(GSK) GlaxoSmithKline’s Flu Vaccine Approved

GlaxoSmithKline(GSK) recently announced the receipt of marketing authorization for its four-strain seasonal influenza vaccine in Germany and the UK. The vaccine will be marketed as Influsplit Tetra in Germany and Fluarix Tetra in the...

18Apr2013 | | Comments Off | Continued

(SNY) Sanofi/Transgene Inks Immunotherapy Deal

Sanofi (SNY) recently entered into a collaboration Transgene for the production of immunotherapy products and creating of an industrial platform for the same. The platform will include Transgene’s candidates. Sanofi and Transgene,...

11Apr2013 | | Comments Off | Continued

(MRK) Pharma & Biotech Stock Outlook – Apr 2013 – Zacks Analyst Interviews

The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE)...

7Apr2013 | | Comments Off | Continued

(NVS) Novartis Drug Candidate Earns Good News

Novartis (NVS) recently announced that the US Food and Drug Administration (FDA) rendered Breakthrough Therapy designation to its pipeline candidate LDK378. The Breakthrough Therapy designation includes all the features involved...

4Apr2013 | | Comments Off | Continued

(BIIB) Biogen’s Tecfidera Approved by U.S. Food and Drug Administration

Tecfidera, Biogen Idec’s (BIIB) oral multiple sclerosis treatment, gained FDA approval recently for the first-line treatment of people with relapsing forms of multiple sclerosis. Biogen intends to launch the drug shortly. Results...

30Mar2013 | | Comments Off | Continued

(SNY) Sanofi Diabetes Drug Under FDA Review

Sanofi (SNY) recently announced that the US Food and Drug Administration (FDA) has accepted the marketing application of its type II diabetes candidate, lixisenatide. The company is looking to get lixisenatide approved for the treatment...

2Mar2013 | | Comments Off | Continued

(AGN) Allergan Earnings Miss but Guidance Tops

Allergan, Inc. (AGN) reported fourth quarter 2012 earnings of $1.15 per share, missing the Zacks Consensus Estimate of $1.19 per share. While earnings increased 15.0% from the year-ago quarter, revenues increased 7.6% to $1,508.9...

24Feb2013 | | Comments Off | Continued

(SNY) Sanofi’s Diabetes Drug Gets EU Nod

Recently, Sanofi (SNY) received encouraging news with the European Commission (EC) approving its diabetes candidate, Lyxumia (lixisenatide). The EC cleared Lyxumia for glycemic control in patients, above 18 years of age, suffering...

18Feb2013 | | Comments Off | Continued

(ABT) AbbVie Provides 2013 Outlook

AbbVie (ABBV) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. AbbVie came into existence earlier this year following its separation from Abbott Laboratories...

18Feb2013 | | Comments Off | Continued

(JNJ) MedTech Industry Stock Outlook – January 2013 – Zacks Analyst Interviews

We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide medical devices market. The US still holds the leading position with almost one-third of the market share. However, emerging economies like Brazil, Russia, India and China –...

31Jan2013 | | Comments Off | Continued

(CEO) Roche Makes Moves in Top Leadership

Switzerland-based Roche (RHHBY) recently announced a few changes in its Corporate Executive Committee. John C. Reed will now head the Pharma Research and Early Development (pRED) division at Roche as the current ad...

23Jan2013 | | Comments Off | Continued

(AZN) Management Expands at AstraZeneca

AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At the same time, two senior roles were discontinued. We note that three of the seven newly created positions are...

22Jan2013 | | Comments Off | Continued

(GSK) GlaxoSmithKline and Theravance Seek European Approval

GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced the submission of a marketing application to the European Medicines Agency (EMA) for their pipeline...

16Jan2013 | | Comments Off | Continued

(MDCO) The Medicines Company Sees Positive Results on Cangrelor

The Medicines Company (MDCO) recently received good news with the company announcing positive results on its phase III candidate, cangrelor. Cangrelor is being developed for the prevention of platelet activation and aggregation that...

15Jan2013 | | Comments Off | Continued

(SNY) Sanofi Updates on Pipeline

Sanofi (SNY) recently provided an update on its pipeline. Sanofi boasts of a robust pipeline with 65 new molecular entities and vaccines in clinical development, of which 17 are in phase III development or under regulatory review. We...

15Jan2013 | | Comments Off | Continued

(ALNY) Alnylam Pharmaceuticals Provides Pipeline Update

Alnylam Pharmaceuticals Inc (ALNY) recently announced its goal for the next two years (2013 and 2014) regarding its key “Alnylam 5×15” pipeline and partner program. Alnylam’s core product strategy, ‘Alnylam 5×15,’...

9Jan2013 | | Comments Off | Continued

(MDVN) Medivation Analyst Neutral on Shares

We recently reiterated a Neutral recommendation on Medivation, Inc. (MDVN). Medivation received a major boost in late August when the FDA approved its prostate cancer treatment, Xtandi, several months ahead of the target date. Xtandi,...

2Jan2013 | | Comments Off | Continued

(SNY) Sanofi Shares Remain Neutral

We are maintaining our Neutral recommendation on Sanofi (SNY). The stock carries a Zacks #3 Rank (Hold) in the short run. Sanofi reported third quarter 2012 business earnings of $1.05 per ADS, above the Zacks Consensus Estimate...

1Jan2013 | | Comments Off | Continued

(NVO) Novo Nordisk’s Ryzodeg Approved in Japan

Denmark based Novo Nordisk (NVO) recently announced that it has received approval in Japan for its diabetes treatment, Ryzodeg (insulin degludec/insulin aspart). Ryzodeg was submitted for regulatory approval...

1Jan2013 | | Comments Off | Continued

(JNJ) Back to Neutral on Bayer

We are reverting to a Neutral recommendation on Bayer (BAYRY) as we believe that all the positive news that led to our previous Outperform recommendation on the stock are reflected in the current price. Bayer performed impressively...

31Dec2012 | | Comments Off | Continued

(MYGN) Myriad Genetics Shares Upgraded to Outperform

Following a strong first quarter result and an encouraging guidance, we upgrade our recommendation on Myriad Genetics (MYGN), provider of molecular diagnostic products, to Outperform with a target price of $33. Myriad started...

24Dec2012 | | Comments Off | Continued

(CHMP) Isis Pharmaceuticals’ Kynamro Earns Negative Report From European Medicines Agency

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend the approval of Isis Pharmaceuticals Inc. (ISIS) and partner Genzyme’s, a Sanofi (SNY)...

19Dec2012 | | Comments Off | Continued

(ISIS) Isis Pharmaceuticals and AstraZeneca Ink Deal

Isis Pharmaceuticals Inc. (ISIS) and AstraZeneca (AZN) recently announced that they have entered into an agreement to discover and develop five new generation antisense...

16Dec2012 | | Comments Off | Continued

(MRK) Merck’s Alzheimer’s Drug Progresses

Merck (MRK) recently moved its Alzheimer’s disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will evaluate the safety and efficacy of MK-8931, an oral ?-amyloid precursor protein site-cleaving enzyme (BACE)...

11Dec2012 | | Comments Off | Continued